Carrier PNA for shRNA delivery into cells by Kitamatsu, Mizuki et al.
 
 
 
 
 
 
 
 
 
 
Carrier PNA for shRNA delivery into cells 
Mizuki Kitamatsu a,*, Takanori Kubo b, Rino Matsuzaki a, Tamaki Endoh a, Takashi 
Ohtsuki a,*, Masahiko Sisido a 
a Department of Bioscience and Biotechnology, Faculty of Engineering, Okayama University, 3-1-1 Tsushimanaka, 
Okayama 700-0082, Japan.  
 b Faculty of Pharmacy, Yasuda Women’s University, 6-13-1, Yasuhigashi, Asaminami, Hiroshima 731-0153, Japan. 
This is where the receipt/accepted dates will go; Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT] 
Abstract— A peptide nucleic acid (PNA)-cell-penetrating peptide (CPP) conjugate (carrier PNA) was used as “bridge-builder” to 
connect a CPP with an shRNA. The carrier PNA successfully formed a hybrid with an shRNA bearing complementary dangling bases and 
the shRNA was introduced into cells by the carrier PNA, and RNAi was induced by the shRNA. 
Short double-stranded RNAs, termed small interfering 
RNAs (siRNAs) or short hairpin RNAs (shRNAs), 
decompose a target mRNA sequence-specifically on the 
basis of RNA interference (RNAi) and downregulate the 
specific gene expression in cells.1 RNAi is commonly 
used as a tool to analyze a genetic function in 
biochemical and medical fields. These RNAs are 
attractive therapeutic candidates for interferring with the 
expression of undesirable genes. Since siRNA and 
shRNA cannot introduce themselves into cells, various 
delivery systems for carrying these RNAs have been 
developed.3 Of these delivery systems, some delivery 
system using cell-penetrating peptides (CPPs) as the 
carriers for RNAs have been reported4 and several 
studies have shown that siRNAs connected with CPPs 
(siRNA-CPPs) entered cells.5 The advantage of this 
method is that an excess amount of RNA carrier 
reagents is not necessary due to the direct connection 
between the siRNAs and the CPP. However, this 
method needs time-consuming synthesis of the siRNA-
CPP for every siRNA. A simpler way to connect the 
CPP and every RNA is needed.  
In this report, we describe a new method to connect an 
siRNA or shRNA with a CPP more simply and rapidly. 
To achieve this purpose, we utilized a peptide nucleic 
acid (PNA).6 The PNA is a peptide-based nucleic acid 
surrogate consisting of nucleobases in the side chain, 
and the PNA can form a more stable hybrid with a 
complementary nucleic acid than nucleic acids 
themselves because of the absence of electrostatic 
repulsion between PNAs and nucleic acids. First, we 
synthesized a PNA conjugated to a CPP (carrier PNA). 
Synthesis of a PNA conjugated to a CPP was much 
easier than synthesis of an siRNA-CPP because both the 
PNA and the CPP can be connected by amide bonds 
from solid-phase peptide synthesis (SPPS). Next, we 
synthesized an shRNA bearing complementary dangling 
bases to the PNA moiety in the carrier PNA. When the 
carrier PNA is mixed with the shRNA, the shRNA 
easily connects to the CPP, resulting in the formation of 
a hybrid between the dangling bases and the PNA 
moiety. This method also has the advantage that the 
carrier PNA can be utilized as a carrier of any shRNA 
and siRNA bearing complementary dangling bases. In 
general, a PNA conjugated to a CPP is used as an 
antisense agent,7 whereas we used the carrier PNA as a 
“bridge-builder” to connect a CPP with an shRNA in 
this work. The carrier PNA was synthesized by Fmoc-
based SPPS.  
The product was identified by MALDI-TOF Mass 
(calcd. [M+H]+ = 3909.87, obsd. [M+H]+ = 3909.92, 
see supplementary information Fig. S1). The chemical 
structure of the carrier PNA is shown in Fig. 1. The 
sequence of PNA is N’-TGGTGCGAA-C’ and the CPP 
is octaarginine (R8). An R8 efficiently translocates 
through the cell membranes and works as a carrier.8 An 
R8 (H-R8-NH2, MALDI-TOF Mass; calcd. [M+H]+ = 
1266.84, obsd. [M+H]+ = 1266.96) and a carrier PNA 
that consists of a different sequence of PNA (carrier 
misPNA; H-PNA(GCAGTGAGT)-ehyleneglycol 
 
spacer-R8-NH2, MALDI-TOF Mass; calcd. [M+H]+ = 
3909.87, obsd. [M+H]+ = 3909.17) were also 
synthesized as references. The structure of an shRNA 
targeted to the firefly luciferase gene (anti-Luc shRNA) 
is also shown in Fig. 1. The anti-Luc shRNA was 
obtained by transcription using T7 RNA polymerase.9 
Dangling bases of the 5’ end in the anti-Luc shRNA are 
complementary with the PNA moiety in the carrier PNA.  
We preliminary investigated whether the carrier PNA 
formed hybrids with nucleic acids. The UV melting 
curve of an equimolar mixture of the carrier PNA and a 
complementary DNA is shown in Fig 2.10 In the case of 
detection at 260 nm derived from nucleobases, it was 
shown that the carrier PNA formed a hybrid with a 
complementary DNA. The melting temperature (Tm) 
was 70.6 ˚C. A UV melting curve of an equimolar 
mixture of carrier PNA without an R8 (H-
PNA(TGGTGCGAA)-NH2) and the complementary 
DNA was also measured. The Tm value was 68.6 ˚C. 
These results indicate that the conjugation of a cationic 
R8 to a PNA does not noticeably affect hybridization of 
the PNA with a complementary DNA. A similar result 
was also reported in a paper on duplex stability of 
DNAs conjugated to a cationic oligomer and a 
complementary DNA.11 Although a UV melting curve 
for an equimolar mixture of the carrier PNA and a 
mismatched DNA was like a sigmoid curve (detection 
at 260 nm), absorbance at 350 nm increased at low 
temperatures, suggesting that aggregation of the carrier 
PNAs and the mismatched DNAs was promoted due to 
electrostatic interactions between CPPs and DNAs 
instead of the formation of a hybrid. Such a rise of 
turbidity was not observed between the carrier PNA and 
the complementary DNA. These results suggest that 
hybridization between the PNA moiety in the carrier 
PNA and the complementary DNA preferentially 
proceeded compared to the nonspecific interaction 
between cationic CPPs and anionic DNAs. These results 
also suggest that the carrier PNA will sequence-
specifically transport nucleic acids into cells.  
Cellular internalization of the hybrid between the carrier 
PNA and a longer DNA was examined by confocal 
laser-scanning microscopy.12 A fluorescence image of 
Chinese hamster ovary (CHO) cells obtain after 
equilibration with hybrids of the carrier PNA with an 
FAM-labeled DNA bearing complementary bases to the 
PNA moiety is shown in Fig. 3a. The intracellular 
location of the hybrid was mostly confined in small 
vesicular compartments. This result indicates that the 
hybrid is successfully introduced into the cells by the 
endosomal pathway. On the other hand, the FAM-
labeled DNA was not internalized with an R8 by the 
cells under same conditions (Fig. 3b). In addition, the 
FAM-labeled DNA alone was not internalized by the 
cells. These results suggest that the PNA moiety has an 
important role in the introduction of specific nucleic 
acids into cells. In other words, these results indicate 
that the nucleic acids were introduced through the 
carrier PNA into cells when the PNA moiety formed a 
hybrid with the nucleic acid.  
We investigated the RNAi effect of an shRNA with the 
carrier PNA in cells.13 The carrier PNA and then an 
anti-Luc shRNA were added to the medium 
supplemented with fetal bovine serum (FBS) on CHO 
cells expressing firefly luciferase (CHO-AA8-Luc cells), 
and the cells were incubated. The final concentrations of 
a mixture of the carrier PNA and the anti-Luc shRNA 
were 250 nM and 500 nM, respectively. Fig. 4a shows 
luciferase expression in the cells. As negative control 
experiments, we also measured luciferase activities of 
cells incubated with the anti-Luc shRNA alone and cells 
incubated with a mixture of the anti-Luc shRNA and a 
carrier PNA containing a mismatched PNA sequence 
(carrier misPNA). Compared to the result of the 
negative control experiments, the anti-Luc shRNA with 
the carrier PNA suppressed luciferase expression to 
22% in the case of 250 nM of the hybrid and to 38% in 
the case of 500 nM of the hybrid.14 Fig. 4b shows that 
the RNAi effect was observed 18-24 h after incubation 
with the carrier PNA/shRNA hybrid. These results 
suggest that the carrier PNA introduced the shRNA into 
cells. The mixture of the carrier misPNA and the anti-
Luc shRNA did not suppress luciferase expression, 
indicating that the shRNA was successfully introduced 
into cells by the carrier PNA via formation of a 
sequence-specific PNA/RNA hybrid.  
In summary, we have developed the new method to 
introduce an shRNA (or siRNA) into cells. The carrier 
PNA successfully formed a hybrid with an shRNA 
bearing complementary dangling bases and the shRNA 
was introduced into cells by the carrier PNA, and then 
RNAi was induced by the shRNA. When shRNAs and 
siRNAs bearing complementary dangling bases are 
prepared, any kinds of RNAs will be introduced by the 
carrier PNA into cells. Escape of the carrier 
PNA/shRNA hybrid from the endosome is currently 
under investigation. 
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Figure 1. Structures of the carrier PNA and the anti-Luc shRNA. A PNA 
is conjugated to a CPP via an ethyleneglycol linker as a spacer. Nine 
dangling bases of the 5’ end of anti-Luc shRNA are shown in red. The 
bases are complementary with the PNA moiety in the carrier PNA.  
 
 
Figure 2. UV melting curves of equimolar mixtures of the carrier PNA 
and DNAs. Solid lines are curves detected at 260 nm, and dotted lines are 
curves detected at 350 nm. The base sequence of the complementary 
DNA is 5’-TTCGCACCA-3’, and the base sequence of the mismatched 
DNA is 5’-ACCACGGAG-3’. 
 
 
Figure 3. Confocal microscopy images of CHO cells cultured for 2 h in 
the presence of 27-mer FAM-labeled DNA bearing complementary 
dangling bases (5’-FAM-CTT CTC AGT TAG GGT TAG TTC GCA 
CCA-3’: complementary sequence underlined) with the carrier PNA (a) 
and with the R8 (b).12 
 
 
Figure 4. (a) RNAi-mediated silencing of firefly luciferase gene in CHO-
AA8-Luc cells by an anti-Luc shRNA with the carrier PNA. The cells 
were incubated with the shRNA and the carrier PNA for 24 h in a 
medium supplemented with 10% FBS. (b) Time dependence of RNAi by 
500 nM carrier PNA/shRNA hybrid. 
 
